NYU Langone Study Uncovers Lung Cancer Cachexia Mechanism via Nervous System Hacking
Event summary
- NYU Langone researchers identified a cachexia-causing pathway in lung cancer linked to the LKB1 gene variant.
- Prostaglandin E2, produced by LKB1-deficient tumors, signals through lung neurons and the vagus nerve to induce cachexia.
- Blocking prostaglandin E2 production with NSAIDs or omega-3 fatty acids improved survival and reduced weight loss in mice.
- Human lung cancer patients with cachexia showed elevated prostaglandin E2 levels, suggesting potential therapeutic targets.
The big picture
This study highlights a novel mechanism by which lung tumors induce cachexia through local neuronal signaling, offering a potential new avenue for treatment. The findings could shift the focus from systemic therapies to targeted interventions that disrupt harmful tumor-nerve communications. NYU Langone's research is part of a broader effort under Cancer Grand Challenges to improve outcomes for cancer patients suffering from cachexia.
What we're watching
- Therapeutic Development
- Whether blocking prostaglandin E2 signaling can translate into effective treatments for human cachexia.
- Clinical Trials
- The pace at which clinical trials will be initiated to test dietary and pharmacological interventions targeting this pathway.
- Intellectual Property
- How NYU Langone's patent applications related to this research will impact future collaborations and commercialization efforts.
Related topics